Labcorp (LH) Stock Price, News & Analysis

Company Overview

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

Key Stats

• Today's Range: $258.39 to $263.51
• 50-Day Range: $212.43 to $263.95
• 52-Week Range: $198.96 to $264.03
• Volume: 597,377 shs
• Average Volume: 636,152 shs
• Market Capitalization: $21.89 billion
• P/E Ratio: 30.24
• Dividend Yield: 1.10%
• Price Target: $274.00
• Consensus Rating: Moderate Buy

Labcorp Stock Analysis - MarketRank™

Labcorp scored higher than 89% of companies evaluated by MarketBeat, and ranked 116th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Labcorp has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 10 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Labcorp has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 9.56%

Earnings Growth

Earnings for Labcorp are expected to grow by 9.56% in the coming year, from $16.01 to $17.54 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Labcorp is 30.24, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.51.

Price to Earnings Ratio vs. Sector

The P/E ratio of Labcorp is 30.24, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.28.

Price to Earnings Growth Ratio

Labcorp has a PEG Ratio of 1.64. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Labcorp has a P/B Ratio of 2.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.73% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Labcorp has recently increased by 11.07%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Labcorp pays a meaningful dividend of 1.11%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Labcorp does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Labcorp is 33.29%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Labcorp will have a dividend payout ratio of 16.42% next year. This indicates that Labcorp will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

3.73% of the float of Labcorp has been sold short.

Short Interest Ratio / Days to Cover

Labcorp has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Labcorp has recently increased by 11.07%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.07

News Sentiment

Labcorp has a news sentiment score of 1.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Labcorp this week, compared to 13 articles on an average week.

Search Interest

Only 3 people have searched for LH on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Labcorp to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Labcorp insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,971,820.00 in company stock.

Percentage Held by Insiders

Only 0.84% of the stock of Labcorp is held by insiders.

Percentage Held by Institutions

95.94% of the stock of Labcorp is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

LH Stock Analysis - Frequently Asked Questions

How have LH shares performed this year?

Labcorp's stock was trading at $229.32 at the beginning of 2025. Since then, LH stock has increased by 14.1% and is now trading at $261.5570.
View the best growth stocks for 2025 here.

How were Labcorp's earnings last quarter?

Labcorp Holdings Inc. (NYSE:LH) issued its earnings results on Tuesday, April, 29th. The medical research company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.73 by $0.11. The company's revenue was up 5.3% compared to the same quarter last year.
Read the conference call transcript.

Does Labcorp have any subsidiaries?

The following companies are subsidiaries of Labcorp: Clinical Outreach Laboratory Services, Personal Genome Diagnostics Inc., Toxikon Corporation, Myriad Autoimmune’s Vectra Testing Business, Ovia Health, Visiun, Envigo's nonclinical contract research services business, and others.

Who are Labcorp's major shareholders?

Labcorp's top institutional investors include Vanguard Group Inc. (11.62%), Select Equity Group L.P. (2.65%), Allspring Global Investments Holdings LLC (2.34%) and Diamond Hill Capital Management Inc. (2.33%). Insiders that own company stock include Adam H Schechter, Glenn A Eisenberg, Brian J Caveney, Lance Berberian, Paul R Kirchgraber, Kerrii B Anderson, Dwight Gary Gilliland, Amy B Summy, Mark S Schroeder, Jonathan P Divincenzo, Der Vaart Sandra D Van and Peter J Wilkinson.
View institutional ownership trends.

How do I buy shares of Labcorp?

Shares of LH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Labcorp own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Labcorp investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 4/29/2025
• Record date for 6/11 Dividend: 5/29/2025
• Dividend Payable: 6/11/2025
• Today: 6/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Health Care Services
• Current Symbol: NYSE:LH
• Previous Symbol: NYSE:LH?
• CIK: 920148
• Web: www.labcorp.com
• Phone: (336) 229-1127
• Fax: 336-513-4510
• Employees: 70,000
• Year Founded: 1995

Price Target and Rating

• Average Stock Price Target: $274.00
• High Stock Price Target: $300.00
• Low Stock Price Target: $230.00
• Potential Upside/Downside: +4.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $8.65
• Trailing P/E Ratio: 30.24
• Forward P/E Ratio: 16.34
• P/E Growth: 1.67
• Net Income: $746 million
• Net Margins: 5.55%
• Pretax Margin: 7.11%
• Return on Equity: 15.27%
• Return on Assets: 6.97%

Debt

• Debt-to-Equity Ratio: 0.68
• Current Ratio: 1.84
• Quick Ratio: 1.60

Sales & Book Value

• Annual Sales: $13.01 billion
• Price / Sales: 1.68
• Cash Flow: $22.45 per share
• Price / Cash Flow: 11.65
• Book Value: $96.27 per share
• Price / Book: 2.72

Miscellaneous

• Outstanding Shares: 83,700,000
• Free Float: 82,997,000
• Market Cap: $21.89 billion
• Optionable: Optionable
• Beta: 0.81